#USA #New Orleans #Nordic Pharma #Lacrifill Gel #Sever Life

Introducing Lacrifill Canalicular Gel

As the American Academy of Ophthalmology (AAO) 2026 convenes in New Orleans from October 9 to 12, Nordic Pharma, Inc., under the SEVER Life Sciences B.V. umbrella, will showcase its innovative Lacrifill® Canalicular Gel. This groundbreaking therapy aims to optimize ocular surface control following procedures such as cataract and refractive surgeries.

Lacrifill's Application in Eye Care

Lacrifill has quickly gained traction within the ophthalmology community, with over 2,200 practices across the U.S. adopting its use. This novel gel has treated more than 130,000 patients, primarily serving those recovering from surgery or managing symptoms of dry eye disease. Patients experiencing these conditions often find relief through Lacrifill, reducing their reliance on traditional drop therapies.

Recent surveys reveal promising patient experiences, with an overwhelming 96% of individuals who underwent cataract surgery reporting improvements in eye comfort since they started using Lacrifill. Notably, 91% of surveyed individuals agreed that the gel positively affected their ocular comfort. Dr. Jai G. Parekh, Chief Commercial Officer of Nordic Pharma, emphasized the importance of AAO as a platform to disseminate these influential findings. "Patients with dry eye disease also report a decreased dependence on both prescription and over-the-counter eye drops after using Lacrifill," he stated.

Patient Insights and Clinical Benefits

The ability to control the ocular surface after surgery is crucial for recovery and overall patient satisfaction. Remarkably, around 83% of patients treated with Lacrifill reported experiencing reduced discomfort post-surgery. Dr. David Szynkarski from the Mann Eye Institute noted the impact of Lacrifill on both patient comfort and clinical outcomes, stating, "Lacrifill canalicular gel allows us to better serve our patients and has contributed to the growth of our practice due to excellent patient outcomes."

The gel is approved for use over an extended period of six months, providing continuous postoperative benefits to patients. During the AAO conference, attendees visiting Nordic Pharma's booth (#3136) will have the opportunity to observe live demonstrations of the application of Lacrifill Canalicular Gel. This interactive experience will further illustrate the gel's administration in practice and its significance in modern eye care.

About SEVER Life Sciences and Nordic Pharma

SEVER Life Sciences B.V., headquartered in the Netherlands, is a global private specialty pharmaceutical company focused on improving lives worldwide. The company comprises three complementary entities, pooling their diverse expertise to provide an array of pharmaceutical products and development services.

Nordic Pharma is uniquely positioned in the biopharmaceutical landscape, collaborating with established global companies to bring innovative medical devices and sterile manufacturing solutions to market. In sharing patient data and experience studies at AAO 2026, Nordic Pharma underscores its commitment to advancing eye care technology and enhancing patient satisfaction.

Conclusion

As Lacrifill Canalicular Gel continues to demonstrate remarkable patient outcomes and satisfaction, its presence at the AAO 2026 will undoubtedly further solidify its role within the ophthalmology community. For more information about Lacrifill Canalicular Gel and ordering details, please visit lacrifill.com.